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In childhood tumors, including retinoblastoma, osteosarcoma, and neuroblastoma, the RB-E2F1 pathway is inactivated, as a rule. 
These tumors arise from precursor cells that fail to undergo the terminal differentiation. Noteworthy, the RB1-encoded protein (RB) 
does not control the cell cycle in embryonic stem cells. It has not been yet well understood how RB controls cell stemness and dif-
ferentiation. The question arises why “inactive” RB is required for the survival and stemness of cells? Recently, we have found that 
overexpression of the RB-binding protein MRPS18-2 (S18-2) in primary fibroblasts leads to their immortalization, which is ac-
companied by the induction of embryonic stem cell markers and, eventually, malignant transformation. We suggest that cell stem-
ness may be associated with high expression levels of both proteins, RB and S18-2. There must be a strict regulation of the expres-
sion levels of S18-2 and RB during embryogenesis. Disturbances in the expression of these proteins would lead to the abnormalities 
in development. We think that the S18-2 protein, together with the RB, plays a crucial role in the control on cell stemness and 
differentiation. We hope to uncover the new mechanisms of the cell fate determination. The S18-2 may serve as a new target for 
anticancer medicines, which will help to improve human health.
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Retinoblastoma is a sporadic or hereditary child-
hood tumor that arises in the retina. Retinoblastoma 
is usually diagnosed at an early age, such as before 
the age of two years in cases of hereditary tumor. 
The age-specific window of retinoblastoma growth 
suggests that tumor formation depends on the pro-
liferation of cells transiently found in the retina (de-
veloping retina) [1]. The main genetic background 
for retinoblastoma is inactivation (mostly deletions) 
of the RB1 gene [2]. The RB1 gene is the first tumor 
suppressor gene that was cloned and its deletion was 
connected with tumor growth. 
The RB1-encoded protein (RB, NP_000312) 
is a phosphoprotein expressed uniformly in all tis-
sues. The RB is a major regulator of the cell cycle, 
blocking entry into the S-phase by binding to E2F1. 
The E2F1 (NP_005216) and several other members 
of E2F family are transcription factors, which transac-
tivate genes required for the entry into the S-phase. 
RB protein binds to E2F1 and inhibits the transcrip-
tional activity of the latter (Fig. 1) [3, 4]. In case of the 
RB phosphorylation, the E2F1 is released from the 
protein complex and performs its function. Hence, 
loss of RB1 leads to uncontrolled cell proliferation. 
Most probably, this explains also retinoblastoma de-
velopment.
Importantly, even if the patients with retinoblastoma 
are cured, they often develop osteosarcomas and 
melanomas later in life. Osteosarcomas, tumors of the 
skeleton, arise from the bone-forming cells; usually 
in the long bones and in the age window of 10–15 years. 
Genetic conditions of osteosarcomas are similar 
to retinoblastomas — mainly deletions of RB1 gene, 
i.e. inactivation of the RB-E2F1 pathway [5]. 
Melanomas develop from the proliferating mela-
noblasts. In melanomas the RB-E2F1 pathway is also 
inactivated, mainly by alterations in the INK locus 
on chromosome 9 [6, 7]. This locus encodes two 
proteins, CDKN2A (p16, NP_000068) and CDKN2B 
(p15, NP_004927); they bind to and inhibit the 
cyclin-dependent kinases CDK4 (NP_000066) and 
CDK6 (NP_001138778). The CDKs phosphorylate 
RB protein. It was shown that promoter regions of the 
CDKN2A and CDKN2B genes are heavily methylated 
in melanomas; consequently, levels of encoded proteins 
drop dramatically. Phosphorylation of RB is not inhibited 
then, resulting in the S-phase progression (see Fig. 1). 
Noteworthy, the E2F1-RB pathway is not functional 
also in one of the most dangerous childhood tumors, 
neuroblastoma. Neuroblastoma, sometimes called 
the embryonic tumor, arises from proliferating neuro-
blasts. It was shown that the MYCN (NP_001280157) 
protein is overexpressed in neuroblastomas. MYCN 
induces transactivation of the ID2 gene. As a result, the 
highly expressed ID2 (NP_002157) protein competes 
with the E2F1 for the binding to RB. As was described 
above, the free E2F1 promotes cell division [8, 9].
Apart from the inactivation of the RB-E2F1 pathway, 
and, presumably, enhanced proliferation of cancerous 
cells, what are the other common features of these four 
tumor types? 
Actually, all of the above-mentioned tumors arise 
from the partially differentiated neural crest stem cells. 
Thus, retinoblastoma in the eye arises due to prolife-
ration of retinoblasts (retinal progenitor cells), which 
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should otherwise specialize into optical nerve cells. 
In other words, the terminal differentiation of retino-
blasts is inhibited.
Fig. 1. The RB protein is a major regulator of the cell cycle. 
RB blocks entry into the S-phase by binding to E2F1. The cyclin-
dependent kinases CDK4 and CDK6 phosphorylate RB, freeing the 
E2F1 from a protein complex. This results in S-phase progression
Moreover, osteosarcoma results from the prolifera-
ting osteoblasts. Normally, osteoblasts should undergo 
terminal differentiation into osteocytes. Melanoma cells 
are the proliferating undifferentiated melanoblasts (me-
lanocyte precursors). Neuroblastoma is formed by pro-
liferating neuroblast precursor cells. Upon the normal 
developmental process, the neuroblast precursor cells 
are destined to differentiate into neurons or die by apop-
tosis. Hence, all these tumors arise from precursor cells 
that fail to undergo the terminal stage of differentiation 
(summarized in Fig. 2). What can be a reason for inhibi-
tion of differentiation, in addition to inactivation of the 
RB-E2F1 pathway, supporting cell division?
Yet unexplainably, the RB protein in embryonic 
stem cells is present mainly in hypo- and hyper-
phosphorylated forms, i.e. not in protein complex 
with the E2F1 [10]. Hence, embryonic cell should 
proliferate upon such conditions. On the other hand, 
loss of RB1 leads to embryonic lethality [11]. It is still 
not well understood how the RB is involved in control 
on cell stemness and differentiation (see [12] for 
review). A question arises why the “inactive” RB is re-
quired for the maintenance of cell stemness and nor-
mal development of a set of tissues?
We propose one of the possible explanations. Earlier, 
we have shown that RB binds to the human mitochondrial 
ribosomal protein MRPS18-2 (NP_054765, S18-2 in the 
text). This binding prevents RB-E2F1 complex forma-
tion, thus promoting S-phase entry (Fig. 3) [13, 14].
Moreover, overexpression of the S18-2 protein 
in primary rat embryonic fibroblasts leads to their im-
mortalization with the induction of embryonic stem cell 
markers [15, 16]. Terminally differentiated primary rat 
skin fibroblasts underwent cell transformation upon 
ectopic expression of the S18-2 protein. The trans-
Fig. 2. Tumors arise from precursor cells that fail to undergo terminal differentiation. The migrating neural crest stem cells are shown 
in black. The migrating cells differentiate upon arrival to their organ of destination: bone (the upper left panel), skin (the lower left 
panel), retina (the upper right panel), and the sympathetic nervous system (the lower right panel). If the terminal differentiation 
of precursor cells is blocked, the tumor arises
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formed cells showed increased telomerase activity, cell 
cycle disturbance, and chromosomal instability [17]. 
We concluded that the S18-2 is an oncoprotein and 
might be involved in carcinogenesis. We have shown 
recently that the S18-2 protein is expressed at high 
levels in endometrial cancers compared to hyperplasia 
and normal endometrium, along with the high level 
of the free E2F1 [18].
Fig. 3. Mitochondrial ribosomal protein S18-2 binds to RB, 
preventing the formation of RB-E2F1 complex, thus promoting 
S-phase entry
Our findings and analysis of the published mi-
croarray data showed the elevated expression of the 
S18-2 in stem and cancerous cells. Interestingly, levels 
of the S18-2 are high in the EBV-transformed B-cells 
and transformed fibroblasts (Fig. 4, indicated by ar-
rows). Besides this, heart, adrenal glands, and skeletal 
muscles showed the high S18-2 levels. The data used 
for the analyses described in Fig. 4 were obtained from 
the GTEx Portal (http://www.gtexportal.org/home) 
on 27/01/2017. 
I n t e r e s t i n g l y ,  u p o n  t h e  a n a l y s i s 
of the S18-2 expression pattern in CCLE (Cancer 
cell line encyclopedia) at Broad Institute web-
site (https://portals.broadinstitute.org/ccle), 
we noticed that the S18-2 expression was quite low 
in cell lines derived from osteosarcomas, neuro-
blastomas, and chondrosarcomas. In melanoma 
cell lines the S18-2 level was high (Fig. 5, indicated 
by arrows). The data used for the analyses described 
in Fig. 5 were obtained from the Broad-Novartis 
CCLE portal (https://portals.broadinstitute.org/ccle) 
on 27/01/2017. Noteworthy, in melanoma the RB-
E2F1 pathway is inactivated not by RB1 loss, i.e. the 
RB protein is present.
Unfortunately, not much data is reported, concer-
ning the molecular mechanisms of chondrosar-
coma development. Few authors reported both, 
loss of RB protein due to loss of heterozygosity 
of RB1 gene [19], and also methylation of the CDKN2A 
promoter [20, 21]. 
The discussed above leads to a hypothesis that 
the RB and S18-2 proteins are involved together in the 
maintenance of cell stemness. Hence, the stem cells 
that could be terminally differentiated should express 
both, RB and S18-2 proteins. 
The downregulation of levels or inhibition of the func-
tion by binding to other proteins of one or both proteins 
would lead to a failure in the differentiation of stem cells 
and, eventually, tumorigenesis. There must be a strict 
control on the expression of the S18-2 and RB: any 
disturbance in the expression (upregulation or down-
regulation) would result in abnormal proliferation and/
or inhibition of differentiation (Fig. 6).
It is feasible to test the proposed hypothesis us-
ing, for example the RB1 knockout mouse fibroblasts 
model. Another possibility is to work with a zebrafish 
model to knock down S18-2. Also, the sub-lines of can-
cer cells derived from retinoblastoma, osteosarcoma, 
Fig. 4. Expression profile of the S18-2 gene (Entrez Gene ID: 28973). The highest levels of the S18-2 were detected in adrenal gland, 
heart and skeletal muscles, as well as in transformed fibroblasts and EBV-transformed lymphocytes (indicated with arrows). RPKM – 
read per kilobase per million mapped reads, normalized to the gene length (see detailed description at http://www.gtexportal.org/home) 
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melanoma, and neuroblastoma, expressing the exo-
genous S18-2 and RB at the high levels could be gene-
rated. The differentiation potential of the obtained cells 
and their tumorigenicity could be tested then.
b
a
c
Fig. 6. RB controls cell stemness and differentiation. (a) 
RB controls cell stemness and differentiation, keeping the bal-
ance of these two processes. Mechanism of regulation is still 
not well understood. (b) Any disturbance in the RB expression 
would result in abnormal proliferation and/or inhibition of dif-
ferentiation. (c) We hypothesize that RB and S18-2 proteins 
cooperate to maintain cell stemness. Hence, the stem cells 
could be characterized by the high expression levels of both, 
RB and S18-2 proteins. If cells loose RB (or S18-2), no termi-
nal differentiation could be achieved. This leads to the tumor 
development then
Concluding, we think that the S18-2 protein, toge-
ther with the RB, plays a crucial role in the control on cell 
stemness and differentiation. We hope to uncover the 
new mechanisms of the cell fate determination. The 
S18-2 may probably serve as a new target for anticancer 
medicines, which will help to improve human health.
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